GlassScriptPhysician profile
Minar Chhetry
NPI 1528412046
$2,569.47
in general payments reported to CMS, 2019-2025
16 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $80.78 · 2023: $1,136 · 2024: $745 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $889.38 | 2022-2025 | Ffrct |
| Amgen INC. | $392.85 | 2022-2025 | Repatha |
| Boston Scientific Corporation | $377.53 | 2021-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $292.88 | 2023-2025 | Lifevest |
| Abbott Laboratories | $147.51 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $131.82 | 2023-2025 | |
| Lantheus Medical Imaging, INC. | $67.03 | 2023-2024 | Definity |
| Novartis Pharmaceuticals Corporation | $62.49 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $55.00 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $31.54 | 2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.64 | 2023 | Jardiance |
| Tactile Systems Technology INC | $22.60 | 2024 | Entre Plus, Flexitouch Plus |
| Kiniksa Pharmaceuticals, LTD. | $21.60 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $20.17 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $18.95 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.48 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minar Chhetry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.